| Keywords: |
cancer survival; graft infection; leukemia, myeloid, acute; allogeneic stem cell transplantation; cancer recurrence; disease free survival; methotrexate; bortezomib; boronic acids; pyrazines; editorial; cyclophosphamide; hematopoietic stem cell transplantation; siblings; acute graft versus host disease; acute leukemia; chronic graft versus host disease; hematologic neoplasms; graft versus host reaction; cancer relapse; t-lymphocyte subsets; tacrolimus; hla typing; graft vs host disease; antigens, cd34; cyclosporin; immunosuppressive agents; hla antigen; lymphocyte depletion; thymocyte antibody; myeloid leukemia; immunoprophylaxis
|
